CLOS
PBYI icon

Compagnie Lombard Odier SCmA’s Puma Biotechnology PBYI Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-100
Closed -$3K – 952
2016
Q1 		$3K Sell
100
-100
-50% -$4.52K ﹤0.01% 940
2015
Q4 		$16K Buy
+200
New +$15.7K ﹤0.01% 818

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Compagnie Lombard Odier SCmA's PBYI Position: Q2 2016 in Review

Compagnie Lombard Odier SCmA sold out of Puma Biotechnology (PBYI) in Q2 2016, closing a stake of 100 shares — an estimated $3K sold.

Compagnie Lombard Odier SCmA first reported a position in PBYI in Q4 2015 and held it in 2 quarters. The position peaked at $16K in Q4 2015. 110 funds tracked by Wall St. Rank hold PBYI as of Q2 2016.

  • Compagnie Lombard Odier SCmA reported no remaining Puma Biotechnology position as of Q2 2016 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 100 Puma Biotechnology shares in Q2 2016, an estimated $3K.
  • Compagnie Lombard Odier SCmA first reported a position in Puma Biotechnology in Q4 2015 and held it in 2 quarters.
  • Compagnie Lombard Odier SCmA's Puma Biotechnology position peaked at $16K in Q4 2015.
  • 110 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2016.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2016, filed 15 Aug 2016.